Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multicentre multinational study

European Journal of Cancer

Volumn 33, Issue 11, 1997, Pages 1767-1773

  Thurlimann B ^a,h   Paridaens, R ^b   Serin, D ^c   Bonneterre, J ^d   Roche H ^e   Murray, R ^f   Di Salle, E ^g   Lanzalone, S ^g   Zurlo, M G ^g   Piscitelli, G ^g  

^a Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c INSTITUT SAINTE CATHERINE   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g PFIZER INC   (United States)

^h NONE

Author keywords

Aromatase inhibitors; Breast cancer; Endocrine treatment; Exemestane

Indexed keywords

AMINOGLUTETHIMIDE; AROMATASE INHIBITOR; EXEMESTANE; TAMOXIFEN;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; EDEMA; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; VERTIGO;

EID: 0345596372     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00283-9     Document Type: Article

References (27)

1. Mouridsen HT. Future developments in the endocrine treatment of advanced breast cancer. In Jonat W, Santen RJ, eds. Aromatase Inhibition: Present and Future. Casterton Hall, The Parthenon Publishing Group, 1991, 99-109.
2. Harris JR, Morrow M, Bonadonna G. Cancer of the Breast. In De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia, J.P. Ljppincott Co., 1993, 1264-1332.
3. Castiglione-Gertsch M, Pampallona S, Varini M, et al. Primary endocrine therapy for advanced breast cancer. To start with tamoxifen or with medroxyprogesterone acetate? Ann Oncol 1993, 4(9), 735-740.
4. Leaning PE, Kvinnsland S. Mechanism of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs 1988, 35, 685-710.
5. Hoeffken K, Kempf H, Miller AA, et al. Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer. Cancer Threat Rep, 1986, 10, 1153-1157.
6. Klijn JGM, Den HD. Aromatase inhibitors. In Cvitkovich E, Droz JP, Armand JP, Oury SKH, eds. Handbook of Chemotherapy in Oncology. Jersey, Scientific Communication International Ltd., 1993, 384-388.
7. Wiseman LR, McTavish D. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer. Drugs 1993, 45, 66-84.
8. Ibrahim NK, Buzdar AU. Aromatase inhibitors: current status. Am J Clin Oncol 1995, 18(5), 407-417.
9. Miller WR. Aromatase inhibitors. Endocrine-related Cancer 1996, 3, 65-79.
10. di Salle E, Giudici D, Briatico G, Oman G. Novel irreversible aromatase inhibitors. Ann NY Acad Sci 1990, 595, 357-367.
11. Giudici D, Ornati G, Briatico G, Buzzetti F, Lombardi P, di Salle E. 6-Methyleneandrosta-1, 4-diene-3, 17-dione (FCE 24304): a new irreversible aromatase inhibitor. J Steroid Biochem 1988, 30, 391-394.
12. di Salle E, Ornati G, Paridaens R, Coombes RC, Lobelle JP, Zurlo MG. Preclinical and clinical pharmacology of the aromatase inhibitor exemestane (FCE 24304). In Motta M and Serio M, eds. Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. Amsterdam, Elsevier Science, 1994, 303-310.
13. Lemmens J, Paridaens R, Thomas J, et al. Phase I Study of Exemestane (FCE 24304), a new aromatase inhibitor in metastatic breast cancer (MBC). Ann Oncol 1994, 5(Suppl. 5), 134.
14. Zilembo N, Noberasco C, Bajetta E, et al. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer 1995, 72, 1007-1012.
15. Johannessen DC, Engan T, di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971) a novel steroidal aromatase inhibitor in postmenopausal breast cancer patients: phase I study. Clin Cancer Res 1997, in press.
16. Lanning PE, Paridaens R, Thürlimann B, Piscitelli G, di Salle E. Exemestane experience in breast cancer treatment. J Steroid Biochem Mol Biol 1997, in press.
17. Murray R, Pitt P. Aromatase inhibition with 4-OH-Androstenedione after prior aromatase inhibition with aminoglulethimide in women with advanced breast cancer. Breast Cancer Res Treat 1995, 35, 249-253.
18. Geisler J, Johannessen DC, Anker G, Lønning PE. Treatment with formestane alone or in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects. Eur J Cancer 1996, 32A(5), 789-792.
19. Lønning PE, Helle SI, Johannessen DC, et al. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-I in post-menopausal breast cancer patients. Clin Endocrinol 1995, 42, 23-30
20. Thürlimann B, Paridaens R, Roche H, et al. Exemestane in postmenopausal pretreated advanced breast cancer: a multicenter Phase-II study in patients with aminoglutethimide (AG) failure. Ann Oncol 1994, 5(S8), 29.
21. Howell A, Mackintosh J, Jones M, et al. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Oncol 1988, 24, 1567-1572.
22. Robertson JF, Williams MR, Todd J, et al. Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 1989, 25, 469-475.
23. Dixon AR, Robertson JF, Jackson L, et al. Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival. BrJ Cancer 1990, 62(5), 868-870.
24. Murray R, Pitt P. Treatment of advanced breast cancer with formestane. Ann Oncol 1994, 5(7), 11-13.
25. Murray R, Pitt P, Potts C. Aromatase inhibition with 4-OH-Androstenedione after multiple previous hormone manipulations in patients with advanced breast cancer. In Pannuti F, Manni A, Robustelli della Cuna G, eds. Clinical Use of Aromatase Inhibitors: Current Data and Future Perspectives Pavia, Italy, EDIMES Publishing, 1992, 40-41.
26. Howell A, Downey S, Andson E. New endocrine therapies for breast cancer. Eur J Cancer 1996, 32A(4), 576-588.
27. Miller WR. The clinical relevance of aromatase activity in breast tumour tissue. In Jonath W, Sandten RJ, eds. Aromatase Inhibition: Present and Future. Lancs, U.K., The Parthenon Publishing Group, 1991, 37-45.